Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 

 

 

Title:  Stable oil-in-water emulsion, process for its manufacture and its use in the cosmetic and dermatological fields

United States Patent:  6,126,948

Inventors:  Simonnet; Jean-Thierry (Paris, FR); Le Verge; Danielle (Vigneux sur Seine, FR); Legret; Sylvie (Chatillon, FR); Hansenne; Isabelle (Paris, FR)

Assignee:  L'Oreal (Paris, FR)

Appl. No.:  041664

Filed:  March 13, 1998

Abstract

A fine and stable emulsion of an oily phase in an aqueous phase containing ionic polymer particles, the oil globules of the emulsion having a mean size of at most 500 nm, a process for the stabilization of fluid emulsions, a process for the preparation of these emulsions and their use in the cosmetic and dermatological fields and more particularly as composition for anti-sun protection.

DETAILED DESCRIPTION OF THE INVENTION

"Ionic polymer" is understood to mean both a homopolymer and a copolymer. The aim of the polymers is in particular to disperse the oily phase in the aqueous phase.

The emulsions according to the invention in particular exhibit the advantage of being able to be very fluid while exhibiting very good stability, even in the absence of a gelling agent.

In addition to the abovementioned advantages (fluidity, stability), the use of the polymer particles as dispersant makes it possible to carry out the stage of dispersion of the oily phase in the aqueous phase under cold conditions, which is simpler and less expensive than conventional processes generally carried out with heating, when surfactants are used. Manufacture under cold conditions makes it possible, for example, to introduce heat-sensitive active agents without risk of degradation of these active agents.

The emulsion of the invention is advantageously devoid of surfactant. Thus, because of the absence of surfactant, this emulsion exhibits the advantage of not being irritating to particularly sensitive skin.

Moreover, the emulsion thus obtained is very fine and exhibits particularly satisfactory sensorial qualities. The mean size of the globules constituting the oily phase is less than 500 nm and it preferably ranges from 150 nm to 300 nm.

The emulsion according to the invention can be very fluid, which means that it can exhibit a viscosity of less than 15,000 cPs (i.e. 15 Pa.s), more preferably still of less than 5000 cPs (i.e. 5 Pa.s) (measured on a Brookfield RVT model DV2 viscometer at 0.5 revolution/minute and with a No. 5 rotor).

Generally, the particles which can be used in the invention can be prepared from an ionic polymer, from a mixture of ionic polymers or from a mixture of at least one ionic polymer and of at least one non- ionic polymer. These polymers must be non-toxic old non-irritating to the skin. In addition, they must be able to disperse in water in the particulate form.

The ionic polymer can be cationic or anionic. It is preferably an anionic polymer. The anionic polymers which can be used in the invention are, for example, polymers of isophthalic acid or of sulphoisophthalic acid and in particular the phthalate/sulphoisophthalate/glycol (for example, diethylene glycol/phthalate/isophthalate/1,4-cyclohexanedimethanol) copolymers sold under the names "Eastman AQ polymer" (AQ35S, AQ38S, AQ55S or AQ48 Ultra) by the company Eastman Chemical.

Advantageously, the ionic polymer particles used according to the invention have a particle size ranging from about 10 to about 400 nm and preferably ranging from 20 to 200 nm, depending on the nature of the ionic polymer.

The particles of these polymers can be used as is or in dispersion in water.

In the emulsions of the invention, use may be made of an amount of polymer particles ranging from about 0.1 to about 10%, preferably from 0.5 to 5% and more preferably from 1 to 2% of the total weight of the composition.

The ratio by weight of the polymer particles to the oily phase advantageously ranges from about 1/5 to about 1/40, and preferably from 1/10 to 1/20. Such a ratio makes it possible to obtain a fluid oil dispersion which is fine, that is to say having globules with a particle size of less than 500 nm, and completely stable.

Another object of the invention is the use of ionic polymer particles for the stabilization of an oil-in-water fluid emulsion containing oil globules having a mean size of at most 500 nm.

The emulsion according to the invention can be used in all fields using this type of pharmaceutical dosage form and in particular in the cosmetic and dermatological fields. When it constitutes a cosmetic and/or dermatological composition, it advantageously contains, in addition, a physiologically acceptable medium. Physiologically acceptable is understood to mean a medium compatible with the skin, the mucous membranes, the nails and the hair.

The emulsions which are the subject of the invention find their application in a great number of cosmetic and/or dermatological treatments of the skin, mucous membranes and hair, including the scalp, in particular for the protection, care, cleansing and making up of the skin and mucous membranes, for the protection and care of the hair and for the therapeutic treatment of the skin, hair and mucous membranes and more especially of the lips.

The emulsions according to the invention can, for example, be used in care or cleansing products for the face in the form of creams or milks or as make-up products (skin and lips) by incorporation of fillers, pigments or dyes. According to a specific embodiment of the invention, the emulsion contains a sunscreen and more particularly constitutes an anti-sun composition intended for the protection of the skin, mucous membranes and/or hair against ultraviolet radiation, in particular against solar radiation.

Consequently, a further object of the invention is the cosmetic use of the emulsion as defined above for the treatment of the skin, mucous membranes and/or hair and/or for the protection of the skin, mucous membranes and/or hair against ultraviolet radiation, in particular solar radiation.

Another object of the invention is the use of the emulsion as defined above for the manufacture of a dermatological composition intended for the treatment of the skin, mucous membranes and/or hair and/or for the protection of the skin, mucous membranes and/or hair against ultraviolet radiation, in particular solar radiation.

A further object of the invention is a treatment process for protecting the skin, mucous membranes and/or hair against ultraviolet radiation, in particular solar radiation, characterized in that it consists in applying an effective amount of the anti-sun composition as defined above to the skin, mucous membranes and/or hair.

The anti-sun compositions contain one or more sunscreens which are active in the UV-A and/or UV-B. These screening agents can be hydrophilic or lipophilic chemical screening agents or can be pigments. By way of examples, the chemical screening agents can be chosen from 2-phenylbenzimidazole-5-sulphonic acid and its salts, cinnamic derivatives, such as, for example, 2-ethylhexyl p-methoxycinnamate, salicylic derivatives, such as, for example, 2-ethylhexyl salicylate and homomethyl salicylate, camphor derivatives, such as, for example, 3-(4-methylbenzylidene)camphor or camphorsulphonic acid-(1,4-divinylbenzene), triazine derivatives, such as 2,4,6-tris[p-(2-ethylhexyloxy-carbony)anilino]-1 ,3,5-triazine, benzophenone derivatives, such as 2-hydroxy-4-methoxybenzophenone, dibenzoylmethane derivatives, such as 4-tert-butyl-4'-methoxydibenzoylmethane, .beta.,.beta.-diphenylacrylate derivatives, such as 2-ethylhexyl .alpha.-cyano-.beta.,.beta.-diphenylacrylate or octocrylene, p-aminobenzoic acid derivatives, such as, for example, octyl para-dimethylaminobenzoate, or menthyl anthranilate. Mention may also be made, as screening agents, of the screening polymers and screening silicones described in Application WO-A-93/04665 and in particular benzotriazole silicones.

Other examples of organic screening agents are disclosed in Patent Application EP-A-0,487,404.

When the anti-sun compositions of the invention contain pigments, the latter can be pigments or nanopigments (mean size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 and 50 nm) of metal oxides, which are coated or non-coated, such as, for example, nanopigments of titanium oxide (amorphous or crystallized in the rutile and/or anatase form), iron oxide, zinc oxide, zirconium oxide or cerium oxide which are all photoprotective agents well known per se which act by physically blocking (reflection and/or scattering) UV radiation. Conventional coating agents are, for example, alumina and/or aluminum stearate. Such coated or non-coated metal oxide nanopigments are disclosed in particular in EP-A-0,5 18,772 and EP-A-0,5 18,773.

These chemical screening agents and/or pigments can optionally be present in compositions other than anti-sun compositions, when a degree of anti-sun protection is desired.

Moreover, it has also been found, unexpectedly, that the emulsions according to the invention make possible photochemical stabilization of chemical sunscreens. A further object of the invention is consequently the use of the emulsion as defined above for the photochemical stabilization of chemical sunscreens.

The nature of the oily phase taking part in the composition of the emulsions according to the invention is not critical and it can thus be composed of all the fatty substances and in particular oils conventionally used in the cosmetic and dermatological fields.

Mention may in particular be made, among oils which can be used in the emulsion of the invention, of, for example, vegetable oils (jojoba or avocado oil), mineral oils (liquid petrolatum), synthetic oils (ethylhexyl palmitate or isopropyl myristate), silicone oils (cyclomethicone) and fluorinated oils. The other fatty substances capable of being present in the oily phase can be, for example, fatty acids, fatty alcohols and waxes (liquid jojoba wax).

The oily phase of the emulsion can be present in an amount of from about 0.1 to about 45% and preferably from 5 to 30% of the total weight of the emulsion.

In addition, in a known way, the emulsions of the invention can contain, besides the sunscreens and the pigments mentioned above, adjuvants usual in the cosmetic or dermatological field, such as active agents, these being hydrophilic or lipophilic, preservatives, antioxidants, fragrances, fillers, colouring materials and lipid vesicles. These adjuvants are used in the proportions usual in the cosmetic or dermatological field, for example from about 0.01 to about 20% of the total weight of the emulsion, and they are, depending on their nature, introduced in the aqueous phase or in the oily phase of the emulsion or alternatively in vesicles. These adjuvants and their concentrations must be such that they do not modify the property desired for the emulsion.

If it is desired to obtain a less fluid emulsion, it is possible to add thereto one or more gelling agents, such as clays, polysaccharide gums (xanthan gum), carboxyvinyl polymers or carbomers. These gelling agents are used at concentrations ranging from about 0.1 to about 10%, preferably from 0.1 to 5% and more preferably from 0.1 to 3% of the total weight of the composition.

The emulsions of the invention can optionally be devoid of solvent. This also favours an only slightly aggressive and non-irritating emulsion suitable for use by people with sensitive skin. However, if necessary, they can contain a solvent, in particular a lower alcohol containing from one to six carbon atoms, more particularly ethanol. The amount of solvent can range up to 30% of the total weight of the composition.

The emulsions according to the invention can be prepared by any appropriate means including a stage of homogenization under pressure. According to a preferred embodiment, the preparation is carried out in two stages.

A further object of the invention is consequently a process for the manufacture of the emulsion which consists, in a first stage, in mixing the aqueous phase, the oily phase and the polymer particles with stirring and, in a second stage, in subjecting the mixture obtained to a homogenization based on the cavitation principle.

In the first stage, the mixture is stirred conventionally, for example in a homogenizer rotating at a speed of between 500 and 5000 revolutions/min, for a time of between 10 and 60 min approximately at a temperature of between 20 and 95oC. approximately.

The homogenization based on the cavitation principle of the second stage is a key stage in the process according to the invention. This homogenization results from the cavitation phenomenon created and maintained within the mixture, then in the liquid form, in moving at a linear velocity of at least 100 m/s.

This homogenization can be carried out by use of a high-pressure homogenizer operating under a pressure ranging from 100 to 1000 bar approximately, preferably from 400 to 700 bar. The principle of use of this type of homogenizer is well known to a person skilled in the art. The homogenization is carried out at ambient temperature by successive passes, generally from 2 to 10 passes, under the pressure used, the mixture being brought back to ambient temperature between each pass.

The homogenization can also be obtained under the effect of ultrasound or alternatively by use of homogenizers equipped with a head of rotor/stator type.

Claim 1 of 18 Claims

What is claimed is:

1. An emulsion of an oily phase in an aqueous phase containing oil globules having a diameter of less than 500 nanometers, wherein said emulsion contains ionic polymer particles in a ratio by weight of the polymer particles to the oily phase of from about 1/5 to about 1/40, and wherein said oil globules are not encapsulated in said polymer particles.

 

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

 

 

[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
[ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
[ Site Map ]